个人中心 - 老虎社区

周大少

IP属地：广东

帖子 · 8帖子 · 8
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 周大少周大少
  ·2025-10-22
  $维升药业-B(02561)$ 合作伙伴Ascendis的隆培生长激素获FDA成人适应症批准，那韦培肽在美获优先审评，侧面印证了TransCon技术平台的全球竞争力，也让我们更看好维升管线的全球潜力
  1,219 评论
  1
  分享
  举报
- 周大少周大少
  ·2025-09-09
  $大行科工(02543)$ 明天得转灯了，40多的涨幅去了一大半
  714 评论
  1
  分享
  举报
- 周大少周大少
  ·2025-09-09
  $阿里巴巴-W(09988)$ 继续有得升
  781 评论
  1
  分享
  举报
- 周大少周大少
  ·2025-09-09
  $维升药业-B(02561)$ 核心产品竞争优势显著，商业化潜力受机构认可维升药业的核心产品隆培促生长素是全球目前唯一一款经临床研究证实优效于生长激素日制剂的长效生长激素。其采用TransCon技术平台，能将治疗频率从每日一次降至每周一次，显著提高患者依从性，且药物可在常温中储存6个月，降低了储存和运输成本。
  1,186 评论
  1
  分享
  举报
- 周大少周大少
  ·2025-08-21
  $谢瑞麟(00417)$ 为啥，业绩爆表了吗
  1,131 评论
  1
  分享
  举报
- 周大少周大少
  ·2025-08-21
  $小米集团-W(01810)$ 要破50吧
  1,047 1
  1
  分享
  举报
- 周大少周大少
  ·2025-08-21
  $维升药业-B(02561)$ 凭借其在内分泌治疗领域高度差异化的产品管线、核心产品临近商业化的爆发点、以及海外合作伙伴验证的技术平台和商业成功，展现了巨大的增长潜力。尽管作为创新药企短期内可能面临市场波动，但其核心产品所处的巨大市场空间、明确的罕见病政策红利以及机构投资者的看好，使其成为长期投资者值得关注的对象。投资者可密切关注其核心产品隆培促生长素的获批进展以及后续商业化表现。
  1,268 评论
  1
  分享
  举报
- 周大少周大少
  ·2025-07-30
  $维升药业-B(02561)$ 稳住啊，不要被大市带偏了
  1,012 评论
  1
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4214400421682690","uuid":"4214400421682690","gmtCreate":1751297233500,"gmtModify":1753854989798,"name":"周大少","pinyin":"zdszhoudashao","introduction":"","introductionEn":null,"signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":12,"tweetSize":8,"questionSize":0,"limitLevel":999,"accountStatus":1,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[],"userBadgeCount":0,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"广东","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":491914686165528,"gmtCreate":1761116956436,"gmtModify":1761116958375,"author":{"id":"4214400421682690","authorId":"4214400421682690","name":"周大少","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4214400421682690","idStr":"4214400421682690"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02561\">$维升药业-B(02561)$ </a> 合作伙伴Ascendis的隆培生长激素获FDA成人适应症批准，那韦培肽在美获优先审评，侧面印证了TransCon技术平台的全球竞争力，也让我们更看好维升管线的全球潜力","listText":"<a href=\"https://laohu8.com/S/02561\">$维升药业-B(02561)$ </a> 合作伙伴Ascendis的隆培生长激素获FDA成人适应症批准，那韦培肽在美获优先审评，侧面印证了TransCon技术平台的全球竞争力，也让我们更看好维升管线的全球潜力","text":"$维升药业-B(02561)$ 合作伙伴Ascendis的隆培生长激素获FDA成人适应症批准，那韦培肽在美获优先审评，侧面印证了TransCon技术平台的全球竞争力，也让我们更看好维升管线的全球潜力","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":1,"link":"https://laohu8.com/post/491914686165528","isVote":1,"tweetType":1,"viewCount":1219,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":476759668892072,"gmtCreate":1757402491031,"gmtModify":1757402492130,"author":{"id":"4214400421682690","authorId":"4214400421682690","name":"周大少","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4214400421682690","idStr":"4214400421682690"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02543\">$大行科工(02543)$ </a> 明天得转灯了，40多的涨幅去了一大半","listText":"<a href=\"https://laohu8.com/S/02543\">$大行科工(02543)$ </a> 明天得转灯了，40多的涨幅去了一大半","text":"$大行科工(02543)$ 明天得转灯了，40多的涨幅去了一大半","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/476759668892072","isVote":1,"tweetType":1,"viewCount":714,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":476757896597728,"gmtCreate":1757402443709,"gmtModify":1757402444804,"author":{"id":"4214400421682690","authorId":"4214400421682690","name":"周大少","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4214400421682690","idStr":"4214400421682690"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/09988\">$阿里巴巴-W(09988)$&nbsp;</a> 继续有得升","listText":"<a href=\"https://laohu8.com/S/09988\">$阿里巴巴-W(09988)$&nbsp;</a> 继续有得升","text":"$阿里巴巴-W(09988)$ 继续有得升","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/476757896597728","isVote":1,"tweetType":1,"viewCount":781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":476758628519968,"gmtCreate":1757402402418,"gmtModify":1757402404065,"author":{"id":"4214400421682690","authorId":"4214400421682690","name":"周大少","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4214400421682690","idStr":"4214400421682690"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02561\">$维升药业-B(02561)$ </a> 核心产品竞争优势显著，商业化潜力受机构认可 维升药业的核心产品隆培促生长素是全球目前唯一一款经临床研究证实优效于生长激素日制剂的长效生长激素。其采用TransCon技术平台，能将治疗频率从每日一次降至每周一次，显著提高患者依从性，且药物可在常温中储存6个月，降低了储存和运输成本。","listText":"<a href=\"https://laohu8.com/S/02561\">$维升药业-B(02561)$ </a> 核心产品竞争优势显著，商业化潜力受机构认可 维升药业的核心产品隆培促生长素是全球目前唯一一款经临床研究证实优效于生长激素日制剂的长效生长激素。其采用TransCon技术平台，能将治疗频率从每日一次降至每周一次，显著提高患者依从性，且药物可在常温中储存6个月，降低了储存和运输成本。","text":"$维升药业-B(02561)$ 核心产品竞争优势显著，商业化潜力受机构认可 维升药业的核心产品隆培促生长素是全球目前唯一一款经临床研究证实优效于生长激素日制剂的长效生长激素。其采用TransCon技术平台，能将治疗频率从每日一次降至每周一次，显著提高患者依从性，且药物可在常温中储存6个月，降低了储存和运输成本。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/476758628519968","isVote":1,"tweetType":1,"viewCount":1186,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":469901829132440,"gmtCreate":1755753456349,"gmtModify":1755754799929,"author":{"id":"4214400421682690","authorId":"4214400421682690","name":"周大少","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4214400421682690","idStr":"4214400421682690"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/00417\">$谢瑞麟(00417)$ </a> 为啥，业绩爆表了吗","listText":"<a href=\"https://laohu8.com/S/00417\">$谢瑞麟(00417)$ </a> 为啥，业绩爆表了吗","text":"$谢瑞麟(00417)$ 为啥，业绩爆表了吗","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/469901829132440","isVote":1,"tweetType":1,"viewCount":1131,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":469900964098416,"gmtCreate":1755753423057,"gmtModify":1755754796849,"author":{"id":"4214400421682690","authorId":"4214400421682690","name":"周大少","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4214400421682690","idStr":"4214400421682690"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$&nbsp;</a> 要破50吧","listText":"<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$&nbsp;</a> 要破50吧","text":"$小米集团-W(01810)$ 要破50吧","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/469900964098416","isVote":1,"tweetType":1,"viewCount":1047,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3496319247829394","authorId":"3496319247829394","name":"笑不川","avatar":"https://static.tigerbbs.com/0101e0164994580cb4a9bd50b573832b","crmLevel":7,"crmLevelSwitch":1,"authorIdStr":"3496319247829394","idStr":"3496319247829394"},"content":"等你们空单下了 就开始猛拉 爆死你们","text":"等你们空单下了 就开始猛拉 爆死你们","html":"等你们空单下了 就开始猛拉 爆死你们"}],"imageCount":0,"langContent":"CN","totalScore":0},{"id":469900631216672,"gmtCreate":1755753139094,"gmtModify":1755754776670,"author":{"id":"4214400421682690","authorId":"4214400421682690","name":"周大少","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4214400421682690","idStr":"4214400421682690"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02561\">$维升药业-B(02561)$ </a> 凭借其在内分泌治疗领域高度差异化的产品管线、核心产品临近商业化的爆发点、以及海外合作伙伴验证的技术平台和商业成功，展现了巨大的增长潜力。尽管作为创新药企短期内可能面临市场波动，但其核心产品所处的巨大市场空间、明确的罕见病政策红利以及机构投资者的看好，使其成为长期投资者值得关注的对象。投资者可密切关注其核心产品隆培促生长素的获批进展以及后续商业化表现。","listText":"<a href=\"https://laohu8.com/S/02561\">$维升药业-B(02561)$ </a> 凭借其在内分泌治疗领域高度差异化的产品管线、核心产品临近商业化的爆发点、以及海外合作伙伴验证的技术平台和商业成功，展现了巨大的增长潜力。尽管作为创新药企短期内可能面临市场波动，但其核心产品所处的巨大市场空间、明确的罕见病政策红利以及机构投资者的看好，使其成为长期投资者值得关注的对象。投资者可密切关注其核心产品隆培促生长素的获批进展以及后续商业化表现。","text":"$维升药业-B(02561)$ 凭借其在内分泌治疗领域高度差异化的产品管线、核心产品临近商业化的爆发点、以及海外合作伙伴验证的技术平台和商业成功，展现了巨大的增长潜力。尽管作为创新药企短期内可能面临市场波动，但其核心产品所处的巨大市场空间、明确的罕见病政策红利以及机构投资者的看好，使其成为长期投资者值得关注的对象。投资者可密切关注其核心产品隆培促生长素的获批进展以及后续商业化表现。","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/469900631216672","isVote":1,"tweetType":1,"viewCount":1268,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":462178189783328,"gmtCreate":1753855088973,"gmtModify":1753855204187,"author":{"id":"4214400421682690","authorId":"4214400421682690","name":"周大少","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4214400421682690","idStr":"4214400421682690"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/02561\">$维升药业-B(02561)$ </a> 稳住啊，不要被大市带偏了","listText":"<a href=\"https://laohu8.com/S/02561\">$维升药业-B(02561)$ </a> 稳住啊，不要被大市带偏了","text":"$维升药业-B(02561)$ 稳住啊，不要被大市带偏了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/462178189783328","isVote":1,"tweetType":1,"viewCount":1012,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}